30 likes | 110 Views
Join Dr. David Mankoff, Chair of Experimental Imaging Sciences Committee, for an in-depth discussion on logistical, production, regulatory, and financial aspects of PET agent distribution in clinical trials and the future of PET imaging compounds.
E N D
David Mankoff, MD, PhD Experimental Imaging Sciences Committee Chair Professor of Radiology University of Washington Seattle Cancer Care Alliance Seattle, Washington Experimental ImagingSciences Committee(EISC)
Questions for Panel • What logistical issues have you run into in the distribution of IND- • based PET agents for clinical trials? (ACRIN and others) • Production issues? • Regulatory, QC, etc? • Financial issues? • What do you see as the pathway for developing and testing new • compounds for PET imaging? • Non-proprietary compounds (e.g., FLT, FMISO, FES) • Proprietary compounds • Industry vs cooperative group/NCI trials? • How do you decide whether to bring a new compound into • commercial production? • What new compounds do you see on the horizon?
Experimental ImagingSciences Committee(EISC) David Mankoff, MD, PhD Experimental Imaging Sciences Committee Chair Professor of Radiology University of Washington Seattle Cancer Care Alliance Seattle, Washington